GlassScriptPhysician profile
Naveed Akhtar
NPI 1912997933
$594.90
in general payments reported to CMS, 2019-2025
12 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.83 · 2021: $42.03 · 2022: $180 · 2023: $164 · 2024: $18.82 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $146.31 | 2025 | Dawnzera |
| Actelion Pharmaceuticals US, INC. | $107.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $79.38 | 2023 | Dupixent |
| Grifols USA, LLC | $56.24 | 2023 | Xembify |
| Abbott Laboratories | $47.80 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $43.83 | 2019 | |
| Genentech USA, INC. | $39.93 | 2022 | |
| Glaxosmithkline, LLC. | $17.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2022 | |
| Amgen INC. | $14.44 | 2023 | Tezspire |
| Optinose US, INC. | $14.11 | 2023 | |
| Biocryst US Sales Co., LLC | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.